Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: A 24-week randomized controlled trial

被引:102
作者
Insull, W
Toth, P
Mullican, W
Hunninghake, D
Burke, S
Donovan, JM
Davidson, MH
机构
[1] GelTex Pharmaceut Inc, Waltham, MA 02451 USA
[2] Baylor Coll Med, Lipid Res Clin, Houston, TX 77030 USA
[3] Midw Inst Clin Res Inc, Indianapolis, IN USA
[4] MediSphere Med Res Ctr, LLC, Evansville, IN USA
[5] Univ Minnesota, Heart Dis Prevent Clin, Minneapolis, MN USA
[6] Chicago Ctr Clin Res, Chicago, IL USA
关键词
D O I
10.4065/76.10.971
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To evaluate the efficacy, tolerability, and safety of colesevelam hydrochloride, a new nonsystemic lipid-lowering agent. Patients and Methods: In this double-blind, placebo-controlled trial performed in 1998, 494 patients with primary hypercholesterolemia (low-density lipoprotein [LDL] cholesterol level greater than or equal to 130 mg/dL and less than or equal to 220 mg/dL) were randomized to receive placebo or colesevelam (2.3 g/d, 3.0 g/d, 3.8 g/d, or 4.5 g/d) for 24 weeks. Fasting serum lipid profiles were measured to assess efficacy. Adverse events were monitored, and discontinuation rates and compliance rates were analyzed. The primary outcome measure was the mean absolute change of LDL cholesterol from baseline to the end of the 24-week treatment period. Results: Colesevelam lowered mean LDL cholesterol levels 9% to 18% in a dose-dependent manner (P < .001), with a median LDL cholesterol reduction of 20% at 4.5 g/d. The reduction in LDL cholesterol levels was maximal after 2 weeks and sustained throughout the study. Mean total cholesterol levels decreased 4% to 10% (P < .001), while median high-density lipoprotein cholesterol levels increased 3% to 4% (P < .001). Median triglyceride levels increased by 5% to 10% in placebo and colesevelam treatment groups relative to baseline (P < .05), but none of these differences were significantly different from placebo. Mean apolipoprotein B levels decreased 6% to 12% in an apparent dose-dependent manner (P<.001). No significant differences occurred in adverse events or discontinuation rates between groups, and compliance rates were between 88% and 92% for all groups. Conclusions: Colesevelam was efficacious, decreasing mean LDL cholesterol levels by up to 18%, and well tolerated without serious adverse events.
引用
收藏
页码:971 / 982
页数:12
相关论文
共 36 条
[31]   EVALUATION OF THE EFFECTIVENESS OF LIPID-LOWERING THERAPY (BILE-ACID SEQUESTRANTS, NIACIN, PSYLLIUM AND LOVASTATIN) FOR TREATING HYPERCHOLESTEROLEMIA IN VETERANS [J].
SCHECTMAN, G ;
HIATT, J ;
HARTZ, A .
AMERICAN JOURNAL OF CARDIOLOGY, 1993, 71 (10) :759-765
[32]   PREVENTION OF CORONARY HEART-DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA [J].
SHEPHERD, J ;
COBBE, SM ;
FORD, I ;
ISLES, CG ;
LORIMER, AR ;
MACFARLANE, PW ;
MCKILLOP, JH ;
PACKARD, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (20) :1301-1307
[33]   CHOLESTYRAMINE PROMOTES RECEPTOR-MEDIATED LOW-DENSITY-LIPOPROTEIN CATABOLISM [J].
SHEPHERD, J ;
PACKARD, CJ ;
BICKER, S ;
LAWRIE, TDV ;
MORGAN, HG .
NEW ENGLAND JOURNAL OF MEDICINE, 1980, 302 (22) :1219-1222
[34]   EFFECTIVENESS OF LOW-DOSE COLESTIPOL THERAPY IN PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA [J].
SUPERKO, HR ;
GREENLAND, P ;
MANCHESTER, RA ;
ANDREADIS, NA ;
SCHECTMAN, G ;
WEST, NH ;
HUNNINGHAKE, D ;
HASKELL, WL ;
PROBSTFIELD, JL .
AMERICAN JOURNAL OF CARDIOLOGY, 1992, 70 (02) :135-140
[35]   Cholesterol lowering and endothelial function [J].
Vogel, RA .
AMERICAN JOURNAL OF MEDICINE, 1999, 107 (05) :479-487
[36]   INDEPENDENT ASSOCIATIONS BETWEEN PLASMA-LIPOPROTEIN SUBFRACTION LEVELS AND THE COURSE OF CORONARY-ARTERY DISEASE IN THE ST-THOMAS ATHEROSCLEROSIS-REGRESSION-STUDY (STARS) [J].
WATTS, GF ;
MANDALIA, S ;
BRUNT, JNH ;
SLAVIN, BM ;
COLTART, DJ ;
LEWIS, B .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1993, 42 (11) :1461-1467